Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 5 min read

How does melanogenesis work?

Melanogenesis is the multistep enzymatic process by which melanocytes produce melanin. This page outlines the tyrosinase-centred mechanism and summarises research into inhibitors studied in silico, in cells, and in anima

peptides-pro Editorial

Melanogenesis is the biosynthetic pathway through which melanocytes convert the amino acid L-tyrosine into melanin pigments. The rate-limiting step is catalysed by tyrosinase (TYR), a copper-dependent monooxygenase that hydroxylates L-tyrosine to L-DOPA and subsequently oxidises L-DOPA to dopaquinone; the downstream reactions that yield eumelanin and pheomelanin proceed largely non-enzymatically or via accessory enzymes. In the research literature, melanogenesis is treated as a targetable pathway, and tyrosinase is described as the key enzyme catalysing its rate-limiting step [2].

The pathway is regulated by a transcription-factor network rather than by tyrosinase abundance alone. Modern cosmetic-science reviews group tyrosinase with microphthalmia-associated transcription factor (MITF) and the melanocortin receptors as major molecular targets governing pigmentation, alongside targets relevant to skin ageing and inflammation [1].

Research Studies

Aminonaphthoquinone-chalcone hybrids and human tyrosinase in silico

Because many tyrosinase inhibitors identified from mushroom sources show limited efficacy against the human enzyme, one study used in silico methods to evaluate aminonaphthoquinone-chalcone hybrids against human tyrosinase. Molecular docking indicated that all 10 hybrids bound with higher affinity than kojic acid, and that six of them (compounds 3, 4, 5, 7, 9 and 10) bound more strongly than the remainder and interacted with amino acid residues inside the tyrosinase active site [2]. These are computational predictions; the evidence block does not report enzyme-activity or cell-culture confirmation for these hybrids.

N-(2-mercaptoethyl)benzamide derivatives and tyrosinase in enzymatic and cell models

A series of N-(2-mercaptoethyl)benzamide (NMEB) derivatives, 1a–1m, was designed as Cu(II) chelators, retaining structural features that allow 2-mercaptomethylbenzimidazole compounds to chelate copper. Derivative 1m inhibited mushroom tyrosinase activity twice as potently as kojic acid in the presence of L-DOPA, and kinetic studies characterised the inhibition mechanisms of three derivatives including 1m. All NMEB derivatives suppressed melanogenesis more potently than kojic acid in B16F10 cells, reducing melanin production in a concentration-dependent manner [3]. The B16F10 line is a murine melanoma model, so the cell findings are not human-cell data.

4-(4-fluorobenzyl)piperazine-acetanilide conjugates and tyrosinase in vitro

A separate series of 4-(4-fluorobenzyl)piperazine derivatives (2a–u) was designed, synthesised and evaluated as tyrosinase inhibitors. In in vitro enzymatic assays using L-DOPA as substrate, several derivatives showed higher inhibitory activity than kojic acid under identical experimental conditions [5].

Cannabidiol-thiosemicarbazone and tyrosinase in human skin-derived cells

CBD-TSC1, a cannabidiol-based thiosemicarbazone derivative, was investigated as a modulator of melanogenesis in human skin-derived cells, with the rationale that existing tyrosinase inhibitors are often limited by low potency, instability or cytotoxicity. The evidence block reports that the compound exhibits dual tyrosinase inhibition and antioxidant activity in that cell model [8].

Coreopsis tinctoria constituents and multi-target enzyme inhibition

An ethnopharmacology-guided study of Coreopsis tinctoria Nutt. (Kunlun snow chrysanthemum), a traditional medicinal and edible plant of the high-altitude regions of Xinjiang, China, used a ligand-fishing approach to identify multi-target enzyme inhibitors from the dried flower heads [7]. The evidence block does not specify which enzymes were engaged or in which model system.

1064-nm Q-switched fractional laser with oral tranexamic acid in melasma

A registered clinical observation examined 1064-nm Q-switched fractional laser combined with oral tranexamic acid for melasma, a common acquired symmetric hyperpigmentation that occurs most often on the face and is more prevalent in females and in darker skin types. The 1064-nm wavelength is absorbed by pigment, leading to damage of pigment and melanocyte; conventional 1064-nm Q-switched treatment of melasma required repeated large-spot, low-energy scanning of the lesion area, with a terminal reaction of redness and a lesion temperature rise of about 2 °C [4]. This is a procedural and pharmacological intervention study, not a study of a research compound.

Microneedle delivery and the melasma microenvironment

Clinically refractory melasma is described as difficult to treat because it is driven by a multidimensional pathological microenvironment that includes melanocyte hyperactivity, aberrant vascular growth, oxidative stress and chronic inflammation, so single-pathway therapies often produce incomplete or transient responses. A bionic intelligent responsive barbed microneedle system was developed to synergistically remodel that microenvironment [6].

Comparison of reported tyrosinase inhibition benchmarks

Test articleModel / methodReported comparison
Aminonaphthoquinone-chalcone hybrids (10 compounds)In silico docking against human tyrosinaseAll 10 bound with higher affinity than kojic acid; 6 bound more strongly than the others [2]
NMEB derivative 1mMushroom tyrosinase, L-DOPA substrateTwice as potent as kojic acid [3]
NMEB derivatives 1a–1mB16F10 murine melanoma cellsMore potent suppression of melanogenesis than kojic acid; concentration-dependent reduction in melanin [3]
4-(4-fluorobenzyl)piperazine derivatives 2a–uIn vitro enzymatic assay, L-DOPA substrateSeveral derivatives more active than kojic acid under identical conditions [5]

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only, and we do not provide dosing or medical guidance. Nothing on this page is a recommendation for use in a person. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp